FDA approves Dupixent (dupilumab) for children with eosinophilic esophagitis
by Lori SolomonThe U.S. Food and Drug Administration has approved Regeneron's Dupixent (dupilumab) for the treatment of pediatric patients (aged one to 11 years) with eosinophilic esophagitis (EoE
Updated on: March 07,2024
FDA approves Dupixent (dupilumab) for children with eosinophilic esophagitis
by Lori SolomonThe U.S. Food and Drug Administration has approved Regeneron's Dupixent (dupilumab) for the treatment of pediatric patients (aged one to 11 years) with eosinophilic esophagitis (EoE
Updated on:March 07,2024
